Neurology
-
Randomized Controlled Trial Multicenter Study
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). ⋯ This study provides Class II evidence that, for people with AD, crenezumab does not significantly improve cognition or function at 18 months. The study is rated Class II because <80% of enrolled patients completed the study.
-
Randomized Controlled Trial Multicenter Study
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS). ⋯ This study provides Class I evidence that for patients with RMS, ofatumumab decreases the number of new MRI gadolinium-enhancing lesions 12 weeks after treatment initiation.
-
Multicenter Study
A multicenter examination and strategic revisions of the Yale Global Tic Severity Scale.
To examine the internal consistency and distribution of the Yale Global Tic Severity Scale (YGTSS) scores to inform modification of the measure. ⋯ The YGTSS exhibits good internal consistency across children and adults. The parallel findings across Motor and Phonic Frequency, Complexity, and Interference dimensions prompted minor revisions to the anchor point description to promote use of the full range of scores in each dimension. Specific minor revisions to the YGTSS Phonic Tic Symptom Checklist were also proposed.